There is insufficient evidence to confirm effectiveness
The study found that 70.1% to 86.9% of participants experienced treatment-emergent adverse events (TEAEs), mainly gastrointestinal (GI), with serious events in 0% to 12.8%
Retatrutide adds GIPR agonism (which augments insulin secretion and modulates central appetite circuits independently) and GCGR agonism (which increases energy expenditure and hepatic fat mobilisation)
However, the relationship between the mutual coordination of PINK1/Parkin and PGC-1 remains controversial
Both drugs also carry a small risk of rare but serious side effects, including pancreatitis and gallbladder disease [10]
Therefore, phytoestrogens and their metabolites, which have been shown to replicate the benefits of endogenous estrogens, and estrogen-based therapies, are considered promising approaches for preventing the onset and progression of neurodegenerative disorders